Page 143 - Genentech News Today

WATERTOWN, Mass., June 20, 2023 -- C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of... | June 20, 2023

WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...

Johnson & Johnson, Estee Lauder and Danaher are why this business of stock picking and running a portfolio can be so daunting.

Alectinib appeared less effective among patients with lung cancer when taken with low-fat yogurt compared with a fuller breakfast or lunch, according to data published in Journal of the National Comprehensive Cancer Network.The study assessed absorption rates of the agent among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer when taken with different types and

Adding talazoparib to standard atezolizumab maintenance can improve PFS in patients with SLFN11+ ES-SCLC, a phase 2 trial suggests.

Columvi (glofitamab) has accelerated approval for relapsed/refractory DLBCL not otherwise specified or LBCL arising from follicular lymphoma.

The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.

The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity.

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.